Early and Late Treatment Failure in Community-Acquired Pneumonia

被引:38
|
作者
Garcia-Vidal, Carolina [1 ]
Carratala, Jordi [1 ]
机构
[1] Univ Barcelona, Infect Dis Serv, Hosp Univ Bellvitge, Hosp Llobregat,IDIBELL, Barcelona 08907, Spain
关键词
Early failure; late failure; community-acquired pneumonia; inflammatory response; biomarkers; C-REACTIVE PROTEIN; PNEUMOCOCCAL PNEUMONIA; HOSPITALIZED-PATIENTS; RISK-FACTORS; FOLLOW-UP; LEVOFLOXACIN; RESISTANCE; ADULTS; EXPRESSION; MANAGEMENT;
D O I
10.1055/s-0029-1202934
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Treatment failure is a matter of great concern in the management of community-acquired pneumonia (CAP). Defined generally as lack of response or clinical deterioration, failure is considered early when it occurs within the first 72 hours and late when it occurs after 72 hours. The reported incidence of treatment failure among hospitalized patients with CAP ranges from 2.4 to 31% for early failure and from 3.9 to 11% for late failure. Most cases of early failure occur because of inadequate host-pathogen responses. Factors associated with treatment failure include high-risk pneumonia, Ever disease, multilobar infiltrates, Legionella pneumonia, gram-negative pneumonia, pleural effusion, cavitation, leucopenia, and discordant antimicrobial therapy. Conversely, influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease have been linked with a lower risk of failure. Treatment failure is associated with high morbidity and mortality rates. Its detection and management require careful clinical assessment. Certain serum biological markers may be helpful to identify patients with a higher risk of deterioration and poor prognosis. Because inadequate host-pathogen responses are responsible for a significant number of failures, strategies aimed at modulating the inflammatory response should be investigated. Discordant therapy can be prevented by rational application of the current antibiotic guidelines.
引用
收藏
页码:154 / 160
页数:7
相关论文
共 50 条
  • [1] Treatment failure in community-acquired pneumonia
    Menendez, Rosario
    Torres, Antoni
    [J]. CHEST, 2007, 132 (04) : 1348 - 1355
  • [2] Early prediction of treatment failure in severe community-acquired pneumonia: The PRoFeSs score
    Pereira, Jose Manuel
    Laszczynska, Olga
    Azevedo, Ana
    Basilio, Carla
    Sousa-Dias, Conceicao
    Mergulhao, Paulo
    Paiva, Jose Artur
    [J]. JOURNAL OF CRITICAL CARE, 2019, 53 : 38 - 45
  • [3] Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
    Endimiani, A
    Brigante, G
    Bettaccini, AA
    Luzzaro, F
    Grossi, P
    Toniolo, AQ
    [J]. BMC INFECTIOUS DISEASES, 2005, 5 (1)
  • [4] Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
    Andrea Endimiani
    Gioconda Brigante
    Alessia A Bettaccini
    Francesco Luzzaro
    Paolo Grossi
    Antonio Q Toniolo
    [J]. BMC Infectious Diseases, 5
  • [5] Treatment of community-acquired pneumonia
    Kolditz, M.
    Halank, M.
    Hoeffken, G.
    [J]. PNEUMOLOGE, 2005, 2 (01): : 34 - 41
  • [6] Treatment of community-acquired pneumonia
    Low, Donald E.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 179 (12) : 1245 - 1246
  • [7] Treatment of community-acquired pneumonia
    Bartlett, J
    [J]. CHEMOTHERAPY, 2000, 46 : 24 - 31
  • [8] Treatment of community-acquired pneumonia
    Lee, Young R.
    Houngue, Coovi
    Hall, Ronald G.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (09) : 1109 - 1121
  • [9] Treatment of community-acquired pneumonia
    Giménez, RAFD
    [J]. MEDICINA CLINICA, 2003, 121 (01): : 36 - 36
  • [10] TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
    LODE, H
    HOFFKEN, G
    KEMMERICH, B
    VOGELHARTMANN, H
    RAHLWES, M
    WAGNER, J
    RUCKDESCHEL, G
    EHRET, E
    [J]. ATEMWEGS-UND LUNGENKRANKHEITEN, 1988, 14 (02) : 89 - 92